Table 4.
Test | Preclinical study | Phase I |
---|---|---|
Drug |
RO4929097 |
MK-0752 |
Methods |
8 mice (leukemia models) were used in each control or treatment group. |
Six adult and two pediatric patients with leukemia (seven with T-ALL and one with AML) received MK-0752 |
Percentages of human CD45+ cells were determined | ||
Results |
No significance in event-free survival [53] |
Limited antitumor activity and major gastrointestinal toxicity |
Comments | [75] | [76] |